Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts.

Han Y, You X, Xing W, Zhang Z, Zou W. · 2018

Read Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. by Han Y, You X, Xing W, Zhang Z, Zou W. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5967329.txt.

Introduction

Han and co-authors review the paracrine and endocrine actions of proteins secreted by bone cells. Their review appeared in Bone Research. The skeleton is remade without pause through life. Osteoblasts, osteocytes, and osteoclasts release proteins that steer that work. These signals guide bone formation, bone breakdown, and blood vessel growth. Osteocytes make sclerostin, which holds back bone formation. Osteoclasts send factors that act back on bone builders.

Some bone proteins act as hormones across the whole body. FGF23 regulates phosphate balance, the authors note. Osteocalcin shapes glucose use, reproduction, and cognition. Lipocalin-2 can suppress appetite through the brain. The review ties the skeleton to many other organs.

Catalog record

CREATORHan Y, You X, Xing W, Zhang Z, Zou W.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE74 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5967329

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Paracrine and endocrine actions of bone—the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts By Yujiao Han, Xiuling You, Wenhui Xing, Zhong Zhang, Weiguo Zou Published in: Bone Research DOI: 10.1038/s41413-018-0019-6 ABSTRACT Abstract The skeleton is a dynamic organ that is constantly remodeled. Proteins secreted from bone cells, namely osteoblasts, osteocytes, and osteoclasts exert regulation on osteoblastogenesis, osteclastogenesis, and angiogenesis in a paracrine manner. Osteoblasts secrete a range of different molecules including RANKL/OPG, M-CSF, SEMA3A, WNT5A, and WNT16 that regulate osteoclastogenesis. Osteoblasts also produce VEGFA that stimulates osteoblastogenesis and angiogenesis. Osteocytes produce sclerostin (SOST) that inhibits osteoblast differentiation and promotes osteoclast differentiation. Osteoclasts secrete factors including BMP6, CTHRC1, EFNB2, S1P, WNT10B, SEMA4D, and CT-1 that act on osteoblasts and osteocytes, and thereby influenceaA osteogenesis. Osteoclast precursors produce the angiogenic factor PDGF-BB to promote the formation of Type H vessels, which then stimulate osteoblastogenesis. Besides, the evidences over the past decades show that at least three hormones or “osteokines” from bone cells have endocrine functions. FGF23 is produced by osteoblasts and osteocytes and can regulate phosphate metabolism. Osteocalcin (OCN) secreted by osteoblasts regulates systemic glucose and energy metabolism, reproduction, and cognition. Lipocalin-2 (LCN2) is secreted by osteoblasts and can influence energy metabolism by suppressing appetite in the brain. We review the recent progresses in the paracrine and endocrine functions of the secretory proteins of osteoblasts, osteocytes, and osteoclasts, revealing connections of the skeleton with other tissues and providing added insights into the pathogenesis of degenerative diseases affecting multiple organs and the drug discovery process. INTRODUCTION The skeleton, accounting for approximately 15% of total human body weight, is one of our largest organ systems in the human body. It has traditionally been considered as a structural organ that provides mechanical support for stature and locomotion in addition to providing protection for vital organs. Bone is also an important reservoir for a number of minerals including calcium, phosphate, magnesium and organic molecules including collagen fibers and amorphous matrix.1,2 To facilitate these classical functions and to maintain the integrity of the skeleton, constant remodeling of its architecture and composition occurs throughout an individual’s lifetime. Bone remodeling involves two distinct processes, removal of old or damaged bone by osteoclasts and its subsequent replacement with new bone by osteoblasts.3,4 Osteoblasts differentiate from mesenchymal stem cells (MSCs) and comprise 5% of all bone cells, which are responsible for the synthesis of type I collagen and the deposition of mineralized matrix to facilitate the formation of bone.5,6 Furthermore, osteoblasts give rise to terminally differentiated osteocytes, the most abundant skeletal cell, which comprise 90% of total bone cells and are embedded in the bone matrix.4 These immobilized osteocytes regulate bone composition through translation of mechanical strain into biochemical signals.7 Osteoclasts originate from hematopoietic stem cells (HSCs)8 and can express vacuolar-ATPases to the ruffled border membrane on the bone surface, where they pump protons into resorption lacunae to dissolve hydroxyapatite. The low pH in the resorption lacunae achieved by the large number of proton pumps activates matrix metalloproteinases (MMPs) and cysteine proteinases to degrade the collagenous bone matrix.9 In addition, the blood vessels in the bone can influence bone formation and provide a niche for HSCs that reside in the bone marrow.10,11 The involvement of angiogenesis has been reported in bone fracture healing and associated with bone-related diseases including osteoporosis, rheumatoid arthritis and bone cancer.12,13 Within the microenvironment niche, osteoblasts, osteocytes, and osteoclasts synthesize and secrete paracrine signaling molecules, including growth factors, cytokines and chemokines to maintain the remodeling and architecture of skeleton. Molecules secreted by osteoblasts and osteocytes which affect osteoclastogenesis include monocyte/macrophage colony-stimulating factor (M-CSF),14–16 receptor activation of NF-кB ligand (RANKL),17–19 anti-osteoclastogenic factors such as osteoprotegerin (OPG), a decoy receptor of RANKL20–22 and Semaphorin 3A (SEMA3A),23 Wnt gene family 5A (WNT5A) and 16 (WNT16) (Fig. 1). Osteocytes have been reported to secret sclerostin (SOST) which inhibits osteoblast differentiation and subsequently bone formation in a paracrine manner24 (Fig. 1). Osteoclast-derived factors, including bone morphogenetic protein 6 (BMP6),25 collagen triple helix repeat containing 1 (CTHRC1),26 EphrinB2 (EFNB2),27 Sphingosine 1-phosphate (S1P),28 Wnt gene family 10b (WNT10B),29 Semaphorin 4D (SEMA4D), and Cardiotrophin-1(CT-1), affect the differentiation and/or functions of osteoblasts and osteocytes (Fig. 1). [Figure: Paracrine actions of osteoblasts, osteocytes, and osteoclasts-derived factors. Molecules secreted by osteoblasts, osteocytes, and osteoclasts influence each other in a paracrine manner to maintain the balance of bone formation and bone resorption. Osteoblasts activate osteoclast formation by expressing M-CSF, RANKL, and WNT5A and inhibit osteoclast activity through OPG, a decoy receptor of RANKL, SEMA3A, and WNT16. Osteocyte-derived SOST inhibits osteoblast differentiation and stimulates osteoclastogenesis. Osteoclasts also secrete coupling factors such as BMP6, CTHRC1, EFNB2, S1P, WNT10B, SEMA4D, and CT-1 to act on osteoblasts and osteocytes and thereby influence bone formation.] The paracrine actions of secretary factors from osteoblasts, osteocytes and osteoclasts allow balancing of bone formation with bone resorption, processes which are also coupled to angiogenesis. Vascular endothelial growth factor A (VEGFA), derived from pre-osteoblasts and chondrocytes, is a major pro-angiogenic factor that can promote proliferation, survival, and migration of endothelial cells (ECs), a major cell population that expresses VEGF receptor 2 (VEGFR2) (Fig. 2).30–32 Platelet-derived growth factor-BB (PDGF-BB), also an angiogenesis factor secreted by pre-osteoclasts, can induce Type H vessel formation and thereby stimulating bone formation (Fig. 2).33 Briefly, these paracrine factors produced by bone cells are released into the extracellular environment and act on nearby cells to maintain bone homeostasis. [Figure: Regulation of angiogenesis by secretory factors from different bone cells. Bone formation and bone resorption are coupled by the process of angiogenesis. Pre-osteoblasts and chondrocytes-derived vascular endothelial growth factor A (VEGFA) can promote proliferation, survival and migration of endothelial cells (ECs), which express VEGF receptor 2 (VEGFR2). Hypoxia-inducible factor 1-α (HIF1α) can induce VEGFA expression in chondrocytes and pre-osteoblasts. Matrix metalloproteases (MMPs) can affect VEGF release from the ECM. Pre-osteoclast-secreted platelet-derived growth factor-BB (PDGF-BB) can induce Type H vessel formation and thereby stimulate bone formation.] In addition to its structural role, the skeleton has also been recognized as an endocrine organ for the hormonal modulation of energy homeostasis. Bone-derived secretory factors comprise an important endocrine system that is finely orchestrated with other organs to ensure homeostatic balance and health.3 Bone-derived fibroblast growth factor 23 (FGF23) was discovered from the information in the genetic analyses of human familial disorders of phosphate homeostasis.34 Subsequent studies have recognized that it is principally secreted by osteoblasts and osteocytes in the skeleton and plays important roles in modulating phosphate homeostasis by inhibiting phosphate reabsorption and 1,25-dihydroxyvitamin D3[1,25(OH)2D3] production in the kidney and suppressing parathyroid hormone (PTH) synthesis in the parathyroid gland which reduces the circulating phosphate levels35,36 (Fig. 3). Through a series of murine genetic manipulations and clinical observations including disease symptoms and drug side effects, osteocalcin (OCN) has been identified as an additional bone-derived endocrine hormone that regulates the biological processes of multiple organs including bone, adipose, liver, muscle, pancreas, testes, and brain1,6,37–44 (Fig. 4). Moreover, the latest research demonstrates that osteoblast-derived lipocalin-2 (LCN2) inhibits food intake by binding to the melanocortin 4 receptor (MC4R) in the hypothalamus and regulates glucose tolerance, insulin sensitivity, and insulin secretion to maintain glucose homeostasis45 (Fig. 5). [Figure: Bone-derived FGF23 regulates phosphate metabolism. FGF23, synthesized by osteoblasts and osteocytes, inhibits phosphate resorption

Read the complete text